<DOC>
	<DOCNO>NCT01088191</DOCNO>
	<brief_summary>The purpose study evaluate safety preliminary efficacy MSB-CAR001 subject recently undergo Anterior Cruciate Ligament Reconstruction</brief_summary>
	<brief_title>Safety Efficacy Study MSB-CAR001 Subjects 6 Weeks Post Anterior Cruciate Ligament Reconstruction</brief_title>
	<detailed_description>This prospective , single center , randomize , double blind , control Phase 1b/2a study design evaluate safety tolerability single injection knee joint two different dos MPCs combine Hyaluronan compare Hyaluronan alone patient recently undergone Anterior Cruciate Ligament Reconstruction . All subject study undergone unilateral ACL reconstruction surgery within six month injury . MSB-CAR001 plus Hyaluronan one two dos Hyaluronan alone inject knee joint . After screen injection visit , subject evaluate clinically within 3 day 28 day surgery , 2 , 3 , 6 , 9 , 12 , 18 , 24 month surgery . The radiographical exam perform 6 , 12 , 18 , 24 month surgery . Subjects evaluate 24 month surgery safety .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Males female least 18 year age , old 40 2 . ACL injury require reconstruction 3 . Have undergone unilateral ACL reconstruction surgery within six month injury ; 4 . Willing able undertake standardize rehabilitation protocol 5 . ACL graft use autograft 6 . Willingness participate followup 24 month time initial treatment 7 . Ability understand willingness sign consent form 1 . Women pregnant breast feed plan become pregnant study 2 . Previous allergic reaction Hyaluronan 3 . Systemic local infection screen visit time study injection 4 . History autoimmune disease , , systemic lupus erythematosus , Addison 's disease , Crohn 's disease , rheumatoid arthritis 5 . Treatment immunosuppression therapy within 6 month prior screen ( visit 1 ) 6 . Acute chronic infectious disease , include limited human immunodeficiency virus ( HIV ) ; 7 . Treatment /or uncompleted followup treatment investigational therapy within 6 month procedure /or intent participate investigational drug cell therapy study 24 month followup period study ; 8 . Recipient prior allogeneic stem cell/progenitor cell therapy 9 . Undergoing simultaneous procedure opposite knee 10 . 20 % great antihuman leukocyte antigen ( HLA ) antibody titer and/or antibody specificity donor HLA antigen ; 11 . Known sensitivity bovine ( cow ) , murine ( mouse ) , chicken product and/or dimethylsulfoxide ( DMSO ) . Previous allergic reaction Hyaluronan ; 12 . History current evidence alcohol drug abuse recreational user illicit drug prescription medication 13 . History prior surgery study knee joint 14 . History malignancy ( exclude basal cell carcinoma successfully excise ) 15 . Chondral lesion note time surgical reconstruction great Grade 1a surface</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Anterior Cruciate Ligament Injury</keyword>
	<keyword>Anterior Cruciate Ligament Reconstruction</keyword>
	<keyword>Adult Stem Cells</keyword>
	<keyword>Mesenchymal precursor cell</keyword>
</DOC>